Rituximab in autoimmune cytopenias: For which patients?

Haematologica

Volumn 87, Issue 2, 2002, Pages 113-114

  Finazzi, Guido ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; RITUXIMAB; STEROID;

AUTOIMMUNE DISEASE; B CELL LYMPHOMA; BACTERIAL INFECTION; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; HUMAN; HYPOTENSION; THROMBOCYTOPENIA; TREATMENT INDICATION; VIRUS INFECTION;

ANEMIA, HEMOLYTIC, AUTOIMMUNE; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BRONCHIAL SPASM; CYTOKINES; DRUG EVALUATION; HUMANS; HYPOTENSION; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 0036178705     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (29)

1. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia
2. Anti-CD20 monoclonal therapy in refractory immune thrombocytopenic purpura
3. Favourable response to therapy with the anti-CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease
4. Rituximab: A very efficient therapy in cold agglutinins and refractory autoimmune haemolytic anaemia associated with CD-20 positive, low-grade lymphoma
5. Remission of severe cold agglutinin disease after rituximab therapy
6. Rituximab in a case of cold agglutinin disease
7. Remission of cold hemagglutinin disease induced after rituximab therapy
8. Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab)
9. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia
10. Treatment with anti-CD20 antibodies of patients with autoimmune thrombocytopenia with or without haemolytic anemia: Worsening in hemoglobin level
11. Rituximab chimeric anti CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura
12. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia
13. Rituxan treatment in patients with immune thrombocytopenic purpura (ITP)
14. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 antibody rituximab
15. Sustained remission of platelet counts following monoclonal anti-CD20 antibody therapy in two cases of idiopathic thrombocytopenia and neutropenia
16. Rituximab
17. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab
18. Acute hepatitis B in a patient with antibodies to hepatis B surface who was receiving rituximab
19. Anti-CD20 monoclonal antibody (rituximab) administration in patients with refractory immunologic thrombocytopenic purpura
20. Acute agranulocytosis (AA) in three patients treated with rituximab for non-Hodgkin lymphoma
21. Exacerbation of lupus while receiving rituximab for chronic refractory thrombocytopenia
22. Rituximab for the treatment of type II mixed cryoglobulinemia
23. Complete molecular remission induced by rituximab in a patient with diffuse large cell lymphoma
24. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients
25. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma
26. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant
27. Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin's lymphoma
28. Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia
29. Rituximab with peripheral blood stem cell transplantation in CD20 lymphoproliferative disorders